Answers are grounded in this paper and cite their sources.
Background: Background: Within a few weeks of application, the chemical carcinogen 7,12 dimethyl benzaanthracene ( DMBA ) causes the development of carcinomas. For pharmaceutical purposes, natural medicines (Cannabinoid), (CBD) made from plant extracts have continued to be produced. Production of all-natural, less dangerous anticarcinogenic compounds that have the potential to lessen the challenges given by neoplastic diseases like leukemic cancer. Aim of the study:- Examination of the antioxidant activity of CBD in male albino rats that were injected with DMBA. Method:- This experiment was conducted on 30 male rats sectioned into 6 groups with 5 each, Group1 (control), Group2 ( olive oil), Group3 ( cannabinoid), Group 4 ( leukemic), Group5 (prophylactic), Group 6 (Treated). Result Compared to the leukemic rat group, both the prophylactic and the CBD-treated groups. CBD was successful in returning normal levels of total white blood cells (WBC), lymphocytes, red blood cells (RBCs), haemoglobin (Hb), platelets, granulocytes, and spleen tissue. Conclusion:- Our results elucidate the ability of CBD to heal the damage caused by the toxicity effect of DMBA in the blood.
No takes yet. Share an insight, caveat, or question.
Alashqar et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: